The American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021)

Virtual 23 April 2021 - 25 April 2021

Bimekizumab triumphs over secukinumab in improving skin clearance in plaque psoriasis

13 Jul 2021 by

Bimekizumab appeared to be more effective than secukinumab in improving skin clearance in patients with moderate-to-severe plaque psoriasis, according to the multinational, phase IIIb BE RADIANT trial presented at AAD 2021.

Bimekizumab triumphs over secukinumab in improving skin clearance in plaque psoriasis

13 Jul 2021

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021 by

Patients with psoriasis may be at an increased risk of contracting COVID-19, according to a study presented at AAD VMX 2021.

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021

M89 regimen improves skin conditions of rosacea

04 Jun 2021 by

Daily application of M89, which contains 89% Vichy volcanic mineralizing water (VVMW) and 0.4% hyaluronic acid, significantly improves skin characteristics in individuals with clinical signs and symptoms of rosacea, according to a study presented at AAD 2021.

M89 regimen improves skin conditions of rosacea

04 Jun 2021

Ruxolitinib improves sleep quality in patients with AD

01 Jun 2021 by

Treatment with ruxolitinib cream improves sleep-related impairment (SRI) and sleep disturbance in adolescent and adult patients with atopic dermatitis (AD), based on two phase III studies presented at AAD 2021.

Ruxolitinib improves sleep quality in patients with AD

01 Jun 2021

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

27 May 2021 by

The high-affinity, humanized, anti-interleukin-23-p19 monoclonal antibody tildrakizumab showed durable efficacy and safety for the treatment of chronic plaque psoriasis, according to the week 256 findings of the reSURFACE 1 trial.

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

27 May 2021

Bimekizumab tops adalimumab in moderate-to-severe plaque psoriasis

25 May 2021 by

Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F, was superior to adalimumab in reducing the severity of plaque psoriasis, according to results of a phase III trial presented at AAD 2021.

Bimekizumab tops adalimumab in moderate-to-severe plaque psoriasis

25 May 2021

Baricitinib BREEZEs through in atopic dermatitis

25 May 2021 by

In adults with moderate-to-severe atopic dermatitis (AD), use of the oral, selective Janus kinase 1/2 inhibitor baricitinib* led to significant improvements in quality of life (QoL) parameters in AD, accordingly to subgroup analyses results of the BREEZE-AD5 trial.

Baricitinib BREEZEs through in atopic dermatitis

25 May 2021